Product Details
AstraZeneca Brilinta (Tikagrelor) 90mg In Pakistan
Brilinta 90mg contains ticagrelor, an oral antiplatelet medicine that belongs to the P2Y12 platelet-inhibitor class. It reduces platelet activation and aggregation, helping prevent the formation of harmful blood clots. It is prescribed for appropriate patients with acute coronary syndrome, a history of heart attack, and certain other cardiovascular or cerebrovascular conditions.
Benefits
- Helps Prevent Blood Clots: Reduces platelet activation and aggregation.
- Cardiovascular Protection: Used to reduce the risk of cardiovascular death, heart attack, and stroke in appropriate patients with acute coronary syndrome or previous myocardial infarction.
- After Stent Placement: Can reduce the risk of stent thrombosis following treatment of acute coronary syndrome.
- Stroke Prevention: 90mg ticagrelor is also used in specific patients with acute ischemic stroke or high-risk TIA for a limited treatment period.
- Oral Formulation: Convenient tablet formulation for prescribed daily treatment.
Specifications
| Specification | Details |
|---|---|
| Brand Name | Brilinta |
| Active Ingredient | Ticagrelor |
| Strength | 90mg |
| Manufacturer/Marketer | AstraZeneca |
| Dosage Form | Film-coated tablet |
| Drug Class | P2Y12 Platelet Inhibitor |
| Route | Oral |
| Main Uses | ACS, history of MI, selected stroke/TIA patients |
| Tablet Description | Round, biconvex, yellow film-coated tablet |
| Prescription Status | Prescription medicine |
The current U.S. prescribing information lists Brilinta in 60mg and 90mg strengths.
How To Use
- Take Brilinta exactly as prescribed by your doctor or cardiologist.
- For acute coronary syndrome or a history of myocardial infarction, the prescribing information specifies a 180mg loading dose followed by 90mg twice daily during the first year, after which the dose is generally 60mg twice daily.
- For certain acute ischemic stroke or high-risk TIA patients, a 180mg loading dose may be followed by 90mg twice daily for up to 30 days.
- Take the tablet with water and follow the exact schedule prescribed.
- Do not stop Brilinta suddenly without medical advice because discontinuation can increase cardiovascular risk.
- Brilinta is generally used with a prescribed daily aspirin dose of 75–100mg, unless your physician recommends a different antiplatelet strategy.
Why Choose Brilinta 90mg?
- Contains ticagrelor, an established P2Y12 antiplatelet medicine.
- Manufactured and marketed by AstraZeneca.
- Available in a clearly defined 90mg strength.
- Used in established treatment protocols for acute coronary syndrome and other appropriate cardiovascular conditions.
- Can help reduce the risk of thrombotic cardiovascular events when prescribed for the appropriate patient.
